The briefing
Moderna and Merck report that patients receiving their experimental mRNA melanoma vaccine alongside standard therapy lived longer without their cancer returning. The companies frame the results as potentially transformative, pending further data and regulatory review.
Original headline
Moderna and Merck's mRNA Melanoma Vaccine Looks Like a Game Changer